Rocatinlimab, a fully human immunoglobulin G1 anti-OX40 monoclonal antibody (Figure 1b) administered subcutaneously, holds promise as a treatment for moderate-to-severe AD. This evidence concerns the gene TNFRSF4 and Alzheimer disease.